Daniel Janney - Jun 8, 2023 Form 4 Insider Report for Krystal Biotech, Inc. (KRYS)

Role
Director
Signature
/s/ Krish Krishnan, as attorney-in-fact for Daniel Janney
Stock symbol
KRYS
Transactions as of
Jun 8, 2023
Transactions value $
-$6,418,077
Form type
4
Date filed
6/9/2023, 07:03 PM
Previous filing
May 30, 2023
Next filing
Jul 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRYS Common Stock Sale -$589K -4.6K -2.93% $127.96 153K Jun 8, 2023 Directly beneficially owned by Alta Bioequities, L.P. F1
transaction KRYS Common Stock Sale -$138K -1.07K -0.7% $129.02 152K Jun 8, 2023 Directly beneficially owned by Alta Bioequities, L.P. F1, F2
transaction KRYS Common Stock Sale -$694K -5.39K -3.55% $128.73 146K Jun 8, 2023 Directly beneficially owned by Alta Bioequities, L.P. F1, F3
transaction KRYS Common Stock Sale -$640K -5K -3.42% $127.96 141K Jun 8, 2023 Directly beneficially owned by Alta Bioequities, L.P. F1
transaction KRYS Common Stock Sale -$1.28M -10K -7.08% $127.96 131K Jun 8, 2023 Directly beneficially owned by Alta Bioequities, L.P. F1
transaction KRYS Common Stock Sale -$639K -5K -3.81% $127.86 126K Jun 8, 2023 Directly beneficially owned by Alta Bioequities, L.P. F1, F4
transaction KRYS Common Stock Sale -$509K -3.94K -3.12% $129.29 122K Jun 9, 2023 Directly beneficially owned by Alta Bioequities, L.P. F1, F5
transaction KRYS Common Stock Sale -$644K -5K -4.09% $128.84 117K Jun 9, 2023 Directly beneficially owned by Alta Bioequities, L.P. F1, F6
transaction KRYS Common Stock Sale -$1.29M -10K -8.52% $128.53 107K Jun 9, 2023 Directly beneficially owned by Alta Bioequities, L.P. F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
F2 The transaction was executed in multiple trades ranging from $129.0000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3 The transaction was executed in multiple trades ranging from $128.5000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4 The transaction was executed in multiple trades ranging from $127.7000 to $128.44. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5 The transaction was executed in multiple trades ranging from $129.0000 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F6 The transaction was executed in multiple trades ranging from $128.5000 to $129.4800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.
F7 The transaction was executed in multiple trades ranging from $127.715 to $129.6100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein.